Cogent Biosciences, Inc. financial data

Symbol
COGT on Nasdaq
Location
275 Wyman Street, 3 Rd Floor, Waltham, MA
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2025 - Aug 5, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 525 % -42.7%
Debt-to-equity 34.5 % +114%
Return On Equity -120 % -79.6%
Return On Assets -89.4 % -55.1%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 140M shares +27.6%
Common Stock, Shares, Outstanding 114M shares +4.19%
Entity Public Float 869M USD -10.2%
Common Stock, Value, Issued 114K USD +4.59%
Weighted Average Number of Shares Outstanding, Basic 114M shares +15.3%
Weighted Average Number of Shares Outstanding, Diluted 114M shares +15.3%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 251M USD +21.9%
General and Administrative Expense 48.8M USD +25.9%
Costs and Expenses 300M USD +22.5%
Operating Income (Loss) -300M USD -22.5%
Nonoperating Income (Expense) 15.6M USD -11.2%
Net Income (Loss) Attributable to Parent -284M USD -25.1%
Earnings Per Share, Basic -2 USD/shares -20.3%
Earnings Per Share, Diluted -2 USD/shares -20.3%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 128M USD +44.6%
Assets, Current 245M USD -33.8%
Property, Plant and Equipment, Net 5.85M USD -20.5%
Operating Lease, Right-of-Use Asset 19.1M USD -9.31%
Other Assets, Noncurrent 4.86M USD 0%
Assets 275M USD -36.1%
Accounts Payable, Current 16.6M USD +85.2%
Employee-related Liabilities, Current 8.13M USD +43.2%
Liabilities, Current 58.4M USD +46%
Operating Lease, Liability, Noncurrent 15.1M USD -9.92%
Other Liabilities, Noncurrent 2.36M USD
Liabilities 120M USD +111%
Accumulated Other Comprehensive Income (Loss), Net of Tax 13K USD
Retained Earnings (Accumulated Deficit) -1B USD -39.4%
Stockholders' Equity Attributable to Parent 155M USD -58.5%
Liabilities and Equity 275M USD -36.1%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -66.5M USD -26.6%
Net Cash Provided by (Used in) Financing Activities 25M USD -88.3%
Net Cash Provided by (Used in) Investing Activities 69.4M USD +6545%
Common Stock, Shares Authorized 300M shares 0%
Common Stock, Shares, Issued 114M shares +4.19%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 27.8M USD -82.9%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 128M USD +44.6%
Deferred Tax Assets, Valuation Allowance 219M USD +39.1%
Operating Lease, Liability 17.5M USD -7.35%
Payments to Acquire Property, Plant, and Equipment 547K USD +681%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -284M USD -25%
Lessee, Operating Lease, Liability, to be Paid 25.2M USD -9.92%
Property, Plant and Equipment, Gross 12.6M USD +4.77%
Operating Lease, Liability, Current 1.66M USD +12.4%
Lessee, Operating Lease, Liability, to be Paid, Year Two 2.7M USD -5.07%
Lessee, Operating Lease, Liability, to be Paid, Year One 2.84M USD +2.19%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 7.77M USD -15.2%
Lessee, Operating Lease, Liability, to be Paid, Year Three 2.13M USD -20.9%
Deferred Tax Assets, Operating Loss Carryforwards 64.3M USD +34.1%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 2.18M USD +2.21%
Preferred Stock, Shares Outstanding 0 shares
Share-based Payment Arrangement, Expense 40.1M USD +8.23%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%